Redwood Wealth Management Group LLC Cuts Stock Position in Eli Lilly and Company $LLY

Redwood Wealth Management Group LLC lowered its position in Eli Lilly and Company (NYSE:LLY) by 3.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,415 shares of the company’s stock after selling 88 shares during the period. Eli Lilly and Company makes up about 0.8% of Redwood Wealth Management Group LLC’s portfolio, making the stock its 28th largest position. Redwood Wealth Management Group LLC’s holdings in Eli Lilly and Company were worth $1,883,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Wealth Preservation Advisors LLC purchased a new position in shares of Eli Lilly and Company in the 1st quarter worth approximately $27,000. Blume Capital Management Inc. grew its position in shares of Eli Lilly and Company by 46.7% in the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after buying an additional 14 shares during the last quarter. IMG Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company in the 2nd quarter worth approximately $35,000. Financial Gravity Asset Management Inc. purchased a new position in shares of Eli Lilly and Company in the 1st quarter worth approximately $40,000. Finally, TD Capital Management LLC grew its position in shares of Eli Lilly and Company by 129.2% in the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after buying an additional 31 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 2.2%

NYSE:LLY opened at $862.96 on Friday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $935.63. The company’s 50 day moving average is $780.74 and its two-hundred day moving average is $771.71. The company has a market cap of $816.76 billion, a PE ratio of 56.40, a P/E/G ratio of 1.21 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same period in the previous year, the business posted $1.18 EPS. The business’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.7%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s payout ratio is presently 39.22%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, Director J Erik Fyrwald acquired 1,565 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was acquired at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gabrielle Sulzberger acquired 117 shares of the firm’s stock in a transaction on Tuesday, August 12th. The shares were acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the purchase, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders acquired 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on LLY shares. The Goldman Sachs Group lifted their price objective on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a research report on Friday, October 10th. Daiwa America downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Morgan Stanley dropped their target price on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a research report on Friday, October 3rd. Hsbc Global Res raised shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $940.00.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.